The present disclosure provides cell populations enriched for CD57 negative T cells, or depleted for CD57 positive cells, and methods for stimulating, cultivating, expanding, and/or genetically engineering cell populations enriched for CD57− T cells or depleted for CD57+ T cells. Also included are methods for generating, isolating, enriching, or selecting CD57− T cells or depleting CD57+ cells, such as by negative selection.

Provided are methods and compositions for obtaining genome-engineered iPSCs, and derivative cells with stable and functional genome editing at selected sites. Also provided are cell populations or clonal cell lines derived from genome-engineered iPSCs, which comprise targeted integration of one or more exogenous polynucleotides, and/or in/dels in one or more selected endogenous genes.

A method for manufacturing T cell populations enriched for cells expressing CD27 and useful in T cell therapy is described. The T cell populations are also useful for a variety of purposes requiring a highly active, long-lived T cell population. Such cells elicit a superior antitumor immune response in vitro and in vivo.

The present invention relates to a universal-type efficient in-vitro amplification method for multiple times of clinical feedback of allogenic DNT cells. In the method of the present invention, the amount of a T cell activator is phased down in a continuous culture process without the need for additional interleukin-4 or AB serum.

The present disclosure provides a population of poly-donor CD4.sup.IL-10 cells generated by genetically modifying CD4.sup.+ T cells from at least three different T cell donors. Further provided are methods of generating the poly-donor CD4.sup.IL-10 cells and methods of using the poly-donor CD4.sup.IL-10 cells for immune tolerization, treating GvHD, cell and organ transplantation, cancer, and other immune disorders.

The present invention provides: a novel method for the production of truly fully human monoclonal antibodies against specific antigens of our choice using isolated human blood cells. These antigens may include but are not limited to peptide sequences found in c-met and TMX2 proteins; an antibody specific for c-met protein produced with said method; an antibody specific for TMX2 protein produced with said method; and a new means and method for the diagnosis, prevention and/or cancer treatment by means of the aforementioned antibodies.

Provided herein are methods for selecting and stimulating a plurality of cells in a sample of cells using column chromatography, and collecting the cells without using additional steps or reagents to facilitate detachment of the cells from the column. In some aspects, the methods provided herein reduce the time needed to generate a population of selected and stimulated cells useful for genetic engineering, and ultimately, cell therapy, compared to existing methods. Also provided are articles of manufacture and apparatus thereof.

Provided herein are compositions comprising CD4.sup.+ stem cell like memory T (T.sub.SCM) cells and their uses in the treatment of cancer, infection and autoimmune disorders.

The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22.

The present invention describes methods and uses of antibodies targeting the Cβ1 or the Cβ2 chain of a TCR, in particular an anti-Cβ1 antibody, for enrichment of T cells expressing a desired antigen-specific recombinant T cell receptor (TCR).